Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 8, 2003. The report details changes in directors' interests in American Depositary Shares (ADSs) and Ordinary Shares, specifically focusing on option exercises, share transfers from employee trusts, and movements in retirement savings plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific transaction prices and share counts related to director compensation and trust activities.
- ADS Exercise Prices: $12.87052 and $16.08708 per ADS.
- ADS Sale Prices: $43.2317 and $42.133 per ADS.
- Retirement Plan Average Price: $41.12 per Ordinary Share ADR.
Material Changes
The primary material change reported is the increase in Dr. J-P Garnier's shareholding following the exercise of share options and subsequent sales to cover tax liabilities.
- Dr. J-P Garnier: Exercised options over 191,743 ADSs (28,582 and 163,161) and sold 134,475 ADSs. His total holding increased by 57,268 ADSs (+102%) to 113,283 ADSs.
- Trust Transfers: The GSK Trust transferred a total of 395,948 Ordinary Shares to participants in various employee share option and incentive plans between May 2 and May 7, 2003.
- Retirement Plan Movement: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in holdings from 18,526,074 to 18,493,207 Ordinary Share ADRs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves strictly as a disclosure of director share transactions and trust movements.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr. J-P Garnier (113,283) and the percentage increase (+102%) following the May 2003 transactions.
- Confirm the aggregate volume of Ordinary Shares transferred from the GSK Trust to employees (395,948 shares) across the reported dates.
- Review the specific share option plans involved (SmithKline Beecham US Executive Share Option Plan 1989, Employee Share Option Plan 1991, and Glaxo Wellcome 1999 Long Term Incentive Plan).
- Check the impact of the US Retirement Savings Plan movement on the total outstanding share count (decrease of 32,867 ADRs).